FEATURE ARTICLES
In one area, the Initiative for New Manufacturing is exploring whether microfactories, championed by the EV industry, can help biopharma iterate facility design faster.
- Rethinking Product Development Through Lipid-Based Formulations
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- The Rise Of The Autonomous Pharma Plant
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- A Peek Into Novo Nordisk's Sustainable Facility Construction Mindset
- At Base Camp: Lilly's Manufacturing Capacity Journey
PHARMA ONLINE WHITE PAPERS
-
![rules, policies, regulatory documents-GettyImages-1438925546]( "Annex 1: Sterile Fill/Finish For Early Phase Clinical Supplies")
Annex 1: Sterile Fill/Finish For Early Phase Clinical SuppliesMeeting stringent requirements for sterile fill/finish operations hinges on robust contamination control strategies, advanced isolator technology, and rigorous integrity testing to ensure patient safety.
-
Transformative Innovation: Advancing Drug Development Using In Silico Modeling3/4/2026
Explore how predictive modeling and in silico strategies can turn complex data into actionable insights that accelerate drug development and reduce risk across the development lifecycle.
-
Rapid, Seamless Upstream Process Development And Scale-Up For CHO-K1 Cells6/28/2024
Accelerate your biotech company's scale-up process while delivering consistent and strong cell growth, productivity, and product quality.
-
Manufacturing Challenges With High Concentration Biologics3/18/2024
Explore key process operations, some of the challenges in manufacturing high-concentration biologics, and factors to consider for process optimization.
-
Solve ATMP Aseptic Filling Challenges With Gloveless Isolators1/9/2026
Human intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.
-
Choosing The Right PCD Configuration For Reliable Sterility Assurance10/16/2025
Accurate PCD configuration ensures sterility assurance. Learn how to align validation strategies with ISO standards, optimize cycle efficiency, and select the right BI format for EO sterilization success.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Automating Mass Spectrometry Analysis To Accelerate Oligonucleotide Drug Development
- Formulation Development Of Enterically Protected Spray Dried Dispersions
- Not Your Typical MES: The Ultimate Guide To Made With MX
- Routine Monitoring Of DNA/mRNA Therapeutics
- Improving API Solubility With Mesoporous Silica
NEWSLETTER ARCHIVE
- 03.07.26 -- Facilities And Cleanrooms Product Showcase
- 03.06.26 -- Rethinking Product Development Through Lipid-Based Formulations
- 03.05.26 -- STREAM Edition: Addressing The Business Side Of GLP-1 Manufacturing
- 03.03.26 -- Driving Fill-Finish Flexibility
- 03.03.26 -- The Rise Of The Autonomous Pharma Plant
INDUSTRY NEWS
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Forma Life Sciences Launches U.S. Based Contract Development And Manufacturing Organization (CDMO) For Oral Solid Dosage Development And Commercial Manufacturing In Irvine, California3/6/2026
Forma Life Sciences, Inc. today announced its launch as an independent, operator-owned contract development and manufacturing organization (CDMO) focused on oral solid dosage formulation development, clinical manufacturing, and commercial drug product manufacturing in the United States.
-
Join Esco At INTERPHEX 20263/3/2026
-
Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas2/26/2026
Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas.
-
Quotient Sciences Extends Commercial Manufacturing Partnership For Ultra-Rare Disease Treatment2/26/2026
Quotient Sciences, a leading integrated CRDMO, announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.
